Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The celebrations began with the unveiling of the Biocon Anthem
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
